Stempoint Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Stempoint Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-96,439	Closed	-$711K	–	93
2025 Q3	$711K	Buy	+96,439	New	+$494K	0.14%	70

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stempoint Capital's CRVS Position: Q4 2025 in Review

Stempoint Capital sold out of Corvus Pharmaceuticals (CRVS) in Q4 2025, closing a stake of 96,439 shares — an estimated $711K sold.

Stempoint Capital first reported a position in CRVS in Q3 2025 and held it in 1 quarter. The position peaked at $711K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRVS as of Q4 2025.

Stempoint Capital reported no remaining Corvus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Stempoint Capital sold 96,439 Corvus Pharmaceuticals shares in Q4 2025, an estimated $711K.
Stempoint Capital first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Stempoint Capital's Corvus Pharmaceuticals position peaked at $711K in Q3 2025.
124 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.